Strategic partnership Leverage Recipharm Advanced Bio’s ATMP focused CDMO capabilities and recent collaboration activity (notably with Fusix Biotech) to approach potential clients developing oncolytic viruses, viral vectors, and other advanced therapies seeking scalable development and manufacturing support.

Expansion momentum Capitalize on the June 2026 collaboration news as social proof of growth and capability expansion; position as a partner capable of accelerating late-stage development and commercialization for next-generation cancer immunotherapies and viral-based modalities.

Financial viability Target mid-market biotechs with revenue traction but seeking CDMO scale; Recipharm Advanced Bio’s revenue range suggests flexibility for project-based and long-term partnerships, offering development, GMP manufacturing, and clinical-to-commercial transition services.

ATMP expertise Highlight specialized capabilities across live viruses, viral vectors, live-biotherapeutics, and nucleic acids (mRNA and plasmid DNA) to win early discussions with companies needing integrated pre-clinical to commercial manufacturing solutions for complex modalities.

Tech-enabled trust Promote robust technical leadership and agile management alongside modern digital infrastructure (WordPress, analytics, tag management, bot protection) as reassurance for partners prioritizing data-driven project tracking, quality, and regulatory compliance.